Viridian Therapeutics (VRDN) Competitor Comparison
We are evaluating the key criteria listed to compare Viridian Therapeutics (VRDN) against its competitors in the Biotechnology industry.
Market Capitalization
118 / 368Gross Profits
237 / 278Total Revenue
259 / 300EBITDA
293 / 337Free Cashflow
290 / 352Quick Ratio
54 / 357Earnings per Share
289 / 359Dividend yield
0 / 6Total Cash
107 / 358Performance 3 years
75 / 368Performance 5 years
67 / 368Performance 10 years
305 / 368Linearity 3 years
48 / 368Linearity 5 years
291 / 368Linearity 10 years
307 / 368Total Rank
365 / 368Dividend Rank
306 / 368Valuation Rank
335 / 368Piotroski Rank
319 / 368Muliplier Rank
234 / 368Dividend yield - VRDN ranking 0 / 6
Obligatory risk notice
We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.